Incyte announced positive Phase 3 inMIND trial results for tafasitamab combined with lenalidomide and rituximab in relapsed or refractory follicular lymphoma (FL). The trial met its primary endpoint, showing a statistically significant improvement in progression-free survival (PFS) compared to the control group. This combination therapy reduced the risk of disease progression, relapse, or death by 57%.
This news is particularly important for FL patients, who face a high relapse risk and limited treatment options after initial therapies fail. Current treatments often focus on managing symptoms and prolonging remission rather than achieving a cure. The inMIND trial results suggest that this combination therapy could significantly extend the time patients live without disease progression, offering a new and potentially more effective treatment approach. This advancement is crucial because it addresses an unmet need in a common subtype of non-Hodgkin lymphoma.
The inMIND trial involved 548 patients and demonstrated a median PFS of 22.4 months for the tafasitamab group compared to 13.9 months for the control group. Independent review confirmed these findings, showing a consistent PFS benefit. Importantly, this improvement was observed across all patient subgroups, regardless of prior treatment history. The therapy was generally well-tolerated, with the most common side effects being neutropenia, diarrhea, COVID-19 infection, and constipation. These side effects are consistent with other immunotherapy combination regimens. Furthermore, the median time to next treatment was not yet reached in the tafasitamab group, suggesting a durable response.
This positive outcome signifies a potential shift in the treatment landscape for relapsed or refractory follicular lymphoma. The combination of tafasitamab, lenalidomide, and rituximab offers a promising new therapeutic option with a significant improvement in PFS. This could lead to a new standard of care for FL patients, offering hope for better outcomes and improved quality of life. While regulatory approval is still pending, these results pave the way for potential submission to regulatory bodies and, if approved, could significantly impact the lives of FL patients.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
